Boehringer Ingelheim presents positive Dulcolax trial data

Boehringer Ingelheim has published new clinical data which supports the efficacy of its bestselling laxative treatment Dulcolax.

According to new information published during Digestive Disease Week 2010, the bisacodyl-based drug has been proven to deliver improvements on all measured symptoms of constipation in a placebo-controlled 268-patient study.

This trial also showed that use of the drug can help patients to experience an improved quality of life, while the safety profile of Dulcolax was also reinforced.

Gastroenterology expert Professor Stefan Muller-Lissner, of Park-Klinik Weissensee in Berlin, said: “Oral bisacodyl proved to be an effective, well-tolerated treatment for patients with constipation.”

According to Boehringer Ingelheim, Dulcolax is currently the best-selling laxative product in the world and has been met with a high level of satisfaction from patients using the treatment.

Earlier this month, the company announced that it will be working together with Micromet to develop a BiTE antibody-based treatment for multiple myeloma.